Sei Investments Co. Sells 3,931 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Sei Investments Co. lessened its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 18.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,893 shares of the company’s stock after selling 3,931 shares during the quarter. Sei Investments Co.’s holdings in Health Catalyst were worth $114,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of HCAT. Nisa Investment Advisors LLC grew its position in Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the last quarter. Perfromance Wealth Partners LLC bought a new position in shares of Health Catalyst in the second quarter worth about $64,000. EntryPoint Capital LLC bought a new position in shares of Health Catalyst in the first quarter worth about $98,000. Virtus Investment Advisers Inc. bought a new position in shares of Health Catalyst in the first quarter worth about $115,000. Finally, XTX Topco Ltd lifted its holdings in Health Catalyst by 48.2% in the second quarter. XTX Topco Ltd now owns 28,420 shares of the company’s stock valued at $182,000 after buying an additional 9,248 shares during the period. Institutional investors own 85.00% of the company’s stock.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Monday, August 5th. The stock was sold at an average price of $6.19, for a total transaction of $32,243.71. Following the completion of the transaction, the chief operating officer now owns 150,006 shares in the company, valued at approximately $928,537.14. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $6.19, for a total value of $32,243.71. Following the completion of the transaction, the chief operating officer now owns 150,006 shares in the company, valued at $928,537.14. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,362 shares of company stock valued at $256,009 in the last ninety days. Company insiders own 2.50% of the company’s stock.

Health Catalyst Stock Performance

Shares of HCAT stock opened at $8.14 on Friday. The firm has a market cap of $492.23 million, a price-to-earnings ratio of -5.43 and a beta of 1.32. The firm’s 50-day simple moving average is $7.49 and its two-hundred day simple moving average is $6.90. Health Catalyst, Inc. has a 52 week low of $5.42 and a 52 week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.08 by $0.04. The company had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. Health Catalyst’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.21) earnings per share. Analysts forecast that Health Catalyst, Inc. will post -0.35 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on HCAT shares. Stephens decreased their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Thursday, August 8th. Piper Sandler dropped their target price on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 26th. JPMorgan Chase & Co. upped their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Evercore ISI upped their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.58.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.